Statistics and Analysis of Drug Intervention Clinical Trials of COVID-19

OBJECTIVE To provide reference for the registration and development of clinical trials based on the statistics and analysis of the drug intervention clinical trials of COVID-19, summarizes the preliminary research basis of related experimental drugs. METHODS Taking the database of Chinese Clinical Trial Registry Center and U.S. National Library of Medicine Clinical Trials as the registration data source, combined with the domestic and foreign literature research, made statistical analysis on the registration time, research type and design, inclusion criteria, sample size, research implementation site, main evaluation indexes, special population test of drug intervention test, and conducted a total study on the antiviral and respiratory diseases of related drugs. RESULTS Till March 5, 2020, 350 clinical trials had been registered, including 199 drug intervention trials, including 30% of chemical drug intervention, 23% of traditional Chinese medicine intervention, 25% of biological product intervention, 9% of combined drug intervention, 75% of randomized parallel control trials, including protease inhibitors, broad-spectrum antiviral drugs, symptomatic treatment drugs, proprietary Chinese medicine and biological agent. CONCLUSION At present, there are a large number of clinical trials registered, which is conducive to the rapid screening of effective clinical drugs, but it is necessary to focus on the ethical review of clinical trials and take effective measures to ensure the scientific and orderly development of clinical trials, and promote the close combination of clinical trials and clinical treatment.